{
  "company": "Qiagen N.V.",
  "ticker": "QGEN",
  "period": {
    "from": "2026-03-27",
    "to": "2026-04-26",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 23,
    "negative": 5,
    "neutral": 32
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for Qiagen N.V. (QGEN) from 2026-03-27 to 2026-04-26. Analyzed 60 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "Dengue Testing Market Size to be Valued at USD 971.11 Million by 2035; Industry Growth is Driven by the Increase in Dengue Cases in Tropical and Sub-tropical Nations Globally | SNS Insider",
      "date": "2026-04-20",
      "source": "news",
      "score": 0.863
    },
    {
      "title": "Molecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share Data",
      "date": "2026-04-07",
      "source": "news",
      "score": 0.832
    },
    {
      "title": "Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics leadership strong enough for growth in U.S. markets?",
      "date": "2026-04-19",
      "source": "alpha_vantage",
      "score": 0.71
    },
    {
      "title": "Qiagen N.V. stock (NL0012169213): Is its diagnostics dominance strong enough to unlock new upside?",
      "date": "2026-04-21",
      "source": "alpha_vantage",
      "score": 0.625
    },
    {
      "title": "Qiagen N.V. stock (NL0012169213): Is its genomics leadership strong enough to unlock new upside?",
      "date": "2026-04-19",
      "source": "alpha_vantage",
      "score": 0.511
    },
    {
      "title": "Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics edge strong enough to unlock new upside?",
      "date": "2026-04-17",
      "source": "alpha_vantage",
      "score": 0.511
    },
    {
      "title": "Qiagen N.V. stock (NL0012169213): Is sample-to-insight leadership strong enough to unlock new upside",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": 0.511
    },
    {
      "title": "How QIAGEN’s (QGEN) Diagnostics Expansion Strengthens Its Takeover Appeal",
      "date": "2026-04-16",
      "source": "news",
      "score": 0.459
    },
    {
      "title": "How QIAGEN’s (QGEN) Diagnostics Expansion Strengthens Its Takeover Appeal",
      "date": "2026-04-16",
      "source": "alpha_vantage",
      "score": 0.459
    },
    {
      "title": "Qiagen N.V. Stock: Oversold Opportunity in Molecular Diagnostics Leader for North American Investors",
      "date": "2026-04-01",
      "source": "alpha_vantage",
      "score": 0.421
    }
  ],
  "top_negative": [
    {
      "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider",
      "date": "2026-04-13",
      "source": "news",
      "score": -0.869
    },
    {
      "title": "Barclays Downgrades Qiagen NV(QGEN.US) to Hold Rating, Cuts Target Price to $44",
      "date": "2026-04-21",
      "source": "alpha_vantage",
      "score": -0.496
    },
    {
      "title": "Precision Trading with Qiagen N.v. (QGEN) Risk Zones",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.273
    },
    {
      "title": "QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance",
      "date": "2026-03-30",
      "source": "alpha_vantage",
      "score": -0.273
    },
    {
      "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider",
      "date": "2026-04-03",
      "source": "news",
      "score": -0.226
    }
  ],
  "raw_data": {
    "total_items": 60,
    "items": [
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Cancer Biomarkers Market Research Report 2026: Asia Pacific is a High-potential Region Fueled by Increased Healthcare Spending, While Genetic and Epigenetic Segments Drive Innovation",
        "description": "Emerging opportunities in the cancer biomarkers market include the growth of personalized oncology, non-invasive diagnostics, and omics technologies. The Asia Pacific is a high-potential region fueled by increased healthcare spending, while genetic and epigen…",
        "url": "https://www.globenewswire.com/news-release/2026/04/23/3279611/28124/en/Cancer-Biomarkers-Market-Research-Report-2026-Asia-Pacific-is-a-High-potential-Region-Fueled-by-Increased-Healthcare-Spending-While-Genetic-and-Epigenetic-Segments-Drive-Innovation.html",
        "date": "2026-04-23",
        "published_at": "2026-04-23T08:02:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.252,
          "confidence": 0.25
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Dengue Testing Market Size to be Valued at USD 971.11 Million by 2035; Industry Growth is Driven by the Increase in Dengue Cases in Tropical and Sub-tropical Nations Globally | SNS Insider",
        "description": "Dengue testing market grows with rising cases, rapid diagnostics, RT-PCR adoption, and strong public health initiatives driving global demand....",
        "url": "https://www.globenewswire.com/news-release/2026/04/20/3276781/0/en/Dengue-Testing-Market-Size-to-be-Valued-at-USD-971-11-Million-by-2035-Industry-Growth-is-Driven-by-the-Increase-in-Dengue-Cases-in-Tropical-and-Sub-tropical-Nations-Globally-SNS-In.html",
        "date": "2026-04-20",
        "published_at": "2026-04-20T09:30:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.863,
          "confidence": 0.86
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "How QIAGEN’s (QGEN) Diagnostics Expansion Strengthens Its Takeover Appeal",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_5731abfc-8a47-465b-a2f9-3c49fda44331",
        "date": "2026-04-16",
        "published_at": "2026-04-16T07:27:28Z",
        "sentiment": {
          "label": "positive",
          "score": 0.459,
          "confidence": 0.46
        }
      },
      {
        "source": "news",
        "source_name": "24/7 Wall St.",
        "title": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, and More",
        "description": "Pre-Market Stock Futures: The futures are trading mixed this morning, after what started as another week of the same old song and dance yesterday, before...",
        "url": "https://247wallst.com/investing/2026/04/14/here-are-tuesdays-top-wall-street-analyst-research-calls-biogen-birkenstock-fastly-ford-lennox-international-netskope-sandisk-tesla-and-more/",
        "date": "2026-04-14",
        "published_at": "2026-04-14T11:58:19Z",
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider",
        "description": "Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies. Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies.",
        "url": "https://www.globenewswire.com/news-release/2026/04/13/3272705/0/en/Companion-Diagnostics-Market-Size-is-Projected-to-Hit-USD-26-38-Billion-by-2035-SNS-Insider.html",
        "date": "2026-04-13",
        "published_at": "2026-04-13T15:30:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.869,
          "confidence": 0.87
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Rapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel Expansion",
        "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Report 2026\" has been added to ResearchAndMarkets.com's offering.",
        "url": "https://www.globenewswire.com/news-release/2026/04/07/3269503/28124/en/Rapid-Growth-in-Cell-Free-Tumor-DNA-Detection-Market-Forecast-to-Reach-5-64-Billion-by-2030-as-Advancements-in-Personalized-Medicine-Propel-Expansion.html",
        "date": "2026-04-07",
        "published_at": "2026-04-07T16:23:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Molecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share Data",
        "description": "Key growth factors include expanding precision oncology programs, genomic data integration, and cloud deployment in healthcare, with strong potential in Asia-Pacific Key growth factors include expanding precision oncology programs, genomic data integration, a…",
        "url": "https://www.globenewswire.com/news-release/2026/04/07/3269500/28124/en/Molecular-Tumor-Board-Solutions-Market-Outlook-2026-2030-2035-with-Competitor-Market-Share-Data.html",
        "date": "2026-04-07",
        "published_at": "2026-04-07T16:15:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.832,
          "confidence": 0.83
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider",
        "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....",
        "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html",
        "date": "2026-04-03",
        "published_at": "2026-04-03T09:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Gene Panel Market Size to Projected Reach USD 17.18 Billion by 2035, Driven by Precision Medicine Adoption – SNS Insider",
        "description": "Rising demand for early disease detection, expanding oncology applications, and rapid advancements in next-generation sequencing technologies propel market growth at 16.69% CAGR. Rising demand for early disease detection, expanding oncology applications, and …",
        "url": "https://www.globenewswire.com/news-release/2026/03/30/3264508/0/en/Gene-Panel-Market-Size-to-Projected-Reach-USD-17-18-Billion-by-2035-Driven-by-Precision-Medicine-Adoption-SNS-Insider.html",
        "date": "2026-03-30",
        "published_at": "2026-03-30T11:12:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "news",
        "source_name": "PR Newswire UK",
        "title": "Human Identification Market worth $1.69 billion by 2031 | MarketsandMarkets™",
        "description": "DELRAY BEACH, Fla., March 27, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Human Identification Market is projected to grow from about USD 1.01 billion in 2026 to USD 1.69 billion by 2031, at a CAGR of 10.9%. Browse 285 market data tables and 60 …",
        "url": "https://www.prnewswire.co.uk/news-releases/human-identification-market-worth-1-69-billion-by-2031--marketsandmarkets-302727035.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T14:01:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Universal Beteiligungs und Servicegesellschaft mbH Sells 559,616 Shares of Qiagen N.V. $QGEN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-universal-beteiligungs-und-servicegesellschaft-mbh-sells-559616-shares-of-qiagen-nv-qgen-2026-04-23/",
        "date": "2026-04-23",
        "summary": "Universal Beteiligungs und Servicegesellschaft mbH reduced its holding in Qiagen N.V. by 24.0% in Q4, selling 559,616 shares and retaining 1,774,467 shares valued at approximately $80.99 million. Qiagen exceeded Q4 earnings estimates with EPS of $0.62 and revenue of $540.4 million, also providing optimistic FY2026 guidance. The stock opened near $39.98, below its moving averages, and holds a \"Hold\" rating from analysts with a consensus target of $53.64.",
        "sentiment_score": 0.276113,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Barclays Downgrades Qiagen NV(QGEN.US) to Hold Rating, Cuts Target Price to $44",
        "url": "https://news.futunn.com/en/post/71475581/barclays-downgrades-qiagen-nv-qgenus-to-hold-rating-cuts-target",
        "date": "2026-04-21",
        "summary": "Barclays has downgraded Qiagen NV (QGEN.US) from an Overweight to a Hold rating and reduced its target price from $50 to $44. This adjustment reflects a more cautious outlook for the company's stock performance.",
        "sentiment_score": -0.416566,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.496,
          "confidence": 0.5
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Is its diagnostics dominance strong enough to unlock new upside?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-is-its-diagnostics-dominance-strong/69227169",
        "date": "2026-04-21",
        "summary": "Qiagen N.V. is a leader in molecular diagnostics, offering tools for genetic material detection and analysis, vital for genomic research and personalized medicine. The company's \"sample to insight\" model, relying on high-margin consumables and automation, provides a stable revenue stream and positions it for growth in areas like liquid biopsies and companion diagnostics. While facing competition from giants like Thermo Fisher and Roche, Qiagen's strong IP, strategic acquisitions, and global dist",
        "sentiment_score": 0.477811,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.625,
          "confidence": 0.62
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more for U.S. investors now?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-molecular-diagnostics-edge/69221736",
        "date": "2026-04-20",
        "summary": "The article highlights Qiagen N.V.'s strategic position in the molecular diagnostics market, emphasizing its \"sample-to-insight\" technology as a stable investment opportunity for U.S. and English-speaking investors. It details how Qiagen's focus on enabling technologies, rather than direct drug development, provides exposure to booming biotech demand with lower volatility and reduced R&D risks. The company's core business model, key growth drivers, competitive advantage, and relevance for intern",
        "sentiment_score": 0.032111,
        "sentiment_label": "Neutral",
        "relevance_score": 0.322329,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. (QGEN) Stock Analysis: Unlocking a 30% Upside Potential in the Diagnostics & Research Sector",
        "url": "https://www.directorstalkinterviews.com/qiagen-n-v-qgen-stock-analysis-unlocking-a-30-upside-potential-in-the-diagnostics-research-sector/4121249504",
        "date": "2026-04-20",
        "summary": "Qiagen N.V. (QGEN) presents a compelling investment opportunity in the diagnostics and research sector with a potential 30% upside. The company, a leader in molecular insights with an $8.5 billion market cap, shows stable financial performance including 3.70% revenue growth and 11.57% return on equity. Analysts maintain a favorable outlook, with an average target price of $53.96, suggesting the stock is currently undervalued.",
        "sentiment_score": 0.617313,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Why does its genomics leadership matter more for U.S. investors now?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-genomics-leadership-matter/69210270",
        "date": "2026-04-20",
        "summary": "Qiagen N.V. (NL0012169213) is highlighted as a compelling investment opportunity for U.S. and English-speaking investors due to its leadership in genomics, particularly in sample preparation and molecular analytics. The company's consumables-driven \"sample-to-insight\" business model generates recurring revenue and high margins, positioning it strongly within high-growth sectors like oncology and infectious disease testing. Analysts maintain favorable views on the stock, emphasizing its resilienc",
        "sentiment_score": 0.603655,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Q3 2025 Qiagen NV Earnings Call Transcript",
        "url": "https://www.gurufocus.com/stock/QGEN/transcripts/3187429",
        "date": "2026-04-19",
        "summary": "This article provides the Q3 2025 earnings call transcript for Qiagen NV (NYSE: QGEN). It highlights key positive points such as exceeding targets with 6% net sales growth, expanding into the AI-driven single-cell market via acquisition, and announcing a $500 million share repurchase. Negative points include a decline in the Asia-Pacific region, currency headwinds, and cautious capital spending impacting instrument sales.",
        "sentiment_score": 0.401861,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Barclays Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $44",
        "url": "https://news.futunn.com/en/post/71527308/barclays-maintains-qiagen-nv-qgenus-with-hold-rating-maintains-target",
        "date": "2026-04-19",
        "summary": "Barclays has maintained its \"Hold\" rating on Qiagen NV (QGEN.US) stock, keeping the target price at $44. This indicates the analyst believes the stock will perform in line with the market and its current valuation is fair.",
        "sentiment_score": 0.009665,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Is its genomics leadership strong enough to unlock new upside?",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/qiagen-n-v-stock-nl0012169213-is-its-genomics-leadership-strong-enough/69205154",
        "date": "2026-04-19",
        "summary": "QIAGEN N.V. is positioned as a leader in molecular diagnostics and sample technologies, offering essential tools for life sciences and healthcare breakthroughs. The company's business model, heavily reliant on high-margin consumables and recurring revenue, provides stability and exposure to the expanding genomics sector and precision medicine. While supported by strong analyst views and market tailwinds, investors should consider risks like reimbursement pressures, competition, and forex volatil",
        "sentiment_score": 0.466883,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Assessing Qiagen (NYSE:QGEN) Valuation After New Diagnostics Launches And Oncology Workflow Expansion",
        "url": "https://www.sahmcapital.com/news/content/assessing-qiagen-nyseqgen-valuation-after-new-diagnostics-launches-and-oncology-workflow-expansion-2026-04-19",
        "date": "2026-04-19",
        "summary": "Qiagen (NYSE:QGEN) is under review after new diagnostic launches and an expanded oncology workflow. The article notes a 30-day share price rebound but also weaker 90-day and multi-year performance. While some valuation models suggest the stock is undervalued, an analysis of its P/E ratio raises a caution flag compared to its direct peers and the broader life sciences group.",
        "sentiment_score": 0.349807,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics leadership strong enough for growth in U.S. markets?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-is-its-molecular-diagnostics-leadership/69199972",
        "date": "2026-04-19",
        "summary": "Qiagen N.V. leads in molecular diagnostics, offering essential tools for labs globally, with a strong focus on a consumables-based model that generates recurring revenue. The company's strategic position in precision medicine, genomics, and infectious disease detection, along with its robust R&D and strategic partnerships, positions it for continued expansion, especially within the U.S. and English-speaking markets. Investors benefit from its defensive healthcare sector traits, stable cash gener",
        "sentiment_score": 0.414757,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.71,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more for U.S. investors now?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-molecular-diagnostics-edge/69193729",
        "date": "2026-04-18",
        "summary": "Qiagen N.V. is positioned as a leader in molecular diagnostics and life sciences tools, offering investors exposure to the growing genomics and precision medicine sectors. The company's \"sample-to-insight\" business model, robust product portfolio, and strong intellectual property provide a defensive yet growth-oriented profile, appealing to U.S. and English-speaking market investors seeking biotech exposure without the typical drug development risks. Analysts generally view Qiagen positively, ci",
        "sentiment_score": 0.02897,
        "sentiment_label": "Neutral",
        "relevance_score": 0.309149,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics edge strong enough to unlock new upside?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-is-its-molecular-diagnostics-edge-strong/69180513",
        "date": "2026-04-17",
        "summary": "This article analyzes Qiagen N.V. (NL0012169213) and its position in the molecular diagnostics and life sciences sectors. It details Qiagen's \"sample-to-insight\" business model, focusing on recurring revenue from consumables and its strategic market positioning in genomics and personalized medicine. The piece also examines product strengths, market drivers, competitive landscape, and risks for investors in English-speaking markets.",
        "sentiment_score": 0.44577,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026",
        "url": "https://www.biospace.com/press-releases/qiagen-to-showcase-new-sample-to-insight-solutions-for-complex-oncology-applications-at-aacr-2026",
        "date": "2026-04-17",
        "summary": "QIAGEN will present its new \"Sample to Insight\" solutions for complex oncology applications at the AACR Annual Meeting 2026 in San Diego. The company will showcase technologies across sample preparation, single-cell analysis, genomic profiling, and data interpretation, including the new QIAsymphony Connect and the AI-grounding QIAGEN Discovery Platform. These innovations aim to standardize workflows, improve reproducibility, and enhance insights in cancer research and molecular diagnostics.",
        "sentiment_score": 0.413143,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Genotyping Market Major Players - QIAGEN NV, Merck KGaA, Eurofins Genomics, BioTek Instruments Inc",
        "url": "https://www.openpr.com/news/4474377/genotyping-market-major-players-qiagen-nv-merck-kgaa",
        "date": "2026-04-16",
        "summary": "The global Genotyping Market is projected to reach US$ 154.35 billion by 2031 from US$ 30.44 billion in 2023, growing at a CAGR of 22.5%. This growth is driven by the rapid adoption of precision medicine, expanding research in biotechnology, and declining costs of genotyping technologies. Key trends include the integration of AI, use in agriculture, and advancements in gene-editing technologies, with North America leading the market.",
        "sentiment_score": 0.787828,
        "sentiment_label": "Bullish",
        "relevance_score": 0.959418,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "How QIAGEN’s (QGEN) Diagnostics Expansion Strengthens Its Takeover Appeal",
        "url": "https://sg.finance.yahoo.com/news/qiagen-qgen-diagnostics-expansion-strengthens-072728999.html",
        "date": "2026-04-16",
        "summary": "QIAGEN (QGEN) is expanding its diagnostic capabilities with a new rapid QIAstat-Dx panel for bloodstream infection syndromic testing, making it a more attractive takeover target. This expansion reinforces the strategic value of its diagnostic platform, following Reuters' report in January 2026 that the company was weighing strategic options due to renewed takeover interest. The combination of product growth and strategic interest suggests QIAGEN remains a strong candidate for acquisition.",
        "sentiment_score": 0.475331,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.459,
          "confidence": 0.46
        }
      },
      {
        "source": "alpha_vantage",
        "title": "How Investors May Respond To Qiagen (QGEN) Entering Rapid Bloodstream Infection Testing With New Panel",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/how-investors-may-respond-to-qiagen-qgen-entering-rapid-bloo",
        "date": "2026-04-16",
        "summary": "QIAGEN N.V. (QGEN) has expanded its QIAstat-Dx platform into rapid bloodstream infection testing with a new CE-IVDR-certified panel, QIAstat-Dx BCID GPF Plus AMR. This move is expected to strengthen Qiagen's syndromic testing menu and align with hospital needs for rapid sepsis management and antimicrobial stewardship. While this expansion is a positive catalyst for QIAstat-Dx adoption, investors should also consider the increasing competition in the syndromic testing market.",
        "sentiment_score": 0.333265,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Barclays Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $44",
        "url": "https://www.moomoo.com/news/post/68339006/barclays-maintains-qiagen-nv-qgenus-with-hold-rating-maintains-target",
        "date": "2026-04-15",
        "summary": "Barclays has maintained its Hold rating on Qiagen NV (QGEN.US) and reiterated its target price of $44. This reflects the firm's ongoing assessment of Qiagen's financial position and market outlook.",
        "sentiment_score": 0.010806,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "How Investors May Respond To Qiagen (QGEN) Entering Rapid Bloodstream Infection Testing With New Panel",
        "url": "https://www.sahmcapital.com/news/content/how-investors-may-respond-to-qiagen-qgen-entering-rapid-bloodstream-infection-testing-with-new-panel-2026-04-16",
        "date": "2026-04-15",
        "summary": "QIAGEN N.V. (QGEN) has expanded its QIAstat-Dx platform into bloodstream infection testing with a new CE-IVDR-certified panel, aiming to identify pathogens and antimicrobial resistance markers rapidly. This move strengthens QIAGEN's infectious disease portfolio and aligns with hospital priorities for sepsis management, though competition in syndromic testing remains a key risk. Investors will be watching how this expansion impacts Qiagen's revenue growth, which is projected to reach $2.5 billion",
        "sentiment_score": 0.307473,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel",
        "url": "https://www.biospectrumasia.com/news/107/27504/qiagen-expands-into-bloodstream-infection-syndromic-testing-with-new-rapid-qiastat-dx-panel.html",
        "date": "2026-04-15",
        "summary": "Qiagen has launched its CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, marking its expansion into syndromic testing for bloodstream infections. This new rapid panel can identify 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers from blood cultures, delivering results in about one hour. The QIAstat-Dx BCID GPF Plus AMR Panel aims to provide critical information for patient management, antimicrobial stewardship, and infection control.",
        "sentiment_score": 0.542789,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.103,
          "confidence": 0.1
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Why does its sample-to-insight business model matter more for U.S.",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-sample-to-insight-business/69154718",
        "date": "2026-04-15",
        "summary": "Qiagen N.V.'s \"sample-to-insight\" business model is increasingly relevant for US investors due to its focus on automated solutions for molecular diagnostics and research, directly supporting precision medicine. This model provides exposure to stable demand from labs and pharma, emphasizing scalable automation and recurring revenue from consumables. Analysts view this approach favorably for its resilience, competitive moat, and alignment with high-growth areas like genomics and infectious disease",
        "sentiment_score": 0.840407,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen launches bloodstream infection testing panel By Investing.com",
        "url": "https://ca.investing.com/news/company-news/qiagen-launches-bloodstream-infection-testing-panel-93CH-4564707",
        "date": "2026-04-14",
        "summary": "QIAGEN N.V. announced the launch of its QIAstat-Dx BCID GPF Plus AMR Panel, entering the syndromic testing market for bloodstream infections. This CE-IVDR-certified panel quickly identifies 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers within about an hour. The company is poised to present this new panel at the ESCMID Global 2026 Congress while also contemplating strategic options, including a potential sale, amidst recent analyst upgrades and leadership",
        "sentiment_score": 0.346087,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN launches bloodstream infection testing panel",
        "url": "https://www.streetinsider.com/Corporate+News/QIAGEN+launches+bloodstream+infection+testing+panel/26311984.html",
        "date": "2026-04-14",
        "summary": "QIAGEN N.V. (NYSE: QGEN) has launched its QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infection testing, a CE-IVDR-certified panel that identifies 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers. This expansion moves QIAGEN's QIAstat-Dx portfolio into bloodstream infection applications, building on its existing respiratory, gastrointestinal, and meningitis testing. The company announced the product launch at the ESCMID Global 2026 Congress and plans",
        "sentiment_score": 0.406444,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel",
        "url": "https://www.businesswire.com/news/home/20260414262531/en/QIAGEN-Expands-Into-Bloodstream-Infection-Syndromic-Testing-With-New-Rapid-QIAstat-Dx-Panel",
        "date": "2026-04-14",
        "summary": "QIAGEN has launched the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, expanding its syndromic testing portfolio into bloodstream infections. This new panel rapidly identifies 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers from positive blood cultures, providing results in about an hour. The expansion aims to facilitate faster clinical decision-making, antimicrobial stewardship, and infection control for bloodstream infections.",
        "sentiment_score": 0.419376,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.103,
          "confidence": 0.1
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Precision Trading with Qiagen N.v. (QGEN) Risk Zones",
        "url": "https://news.stocktradersdaily.com/news_release/134/Precision_Trading_with_Qiagen_N.v._QGEN_Risk_Zones_041426091002_1776172202.html",
        "date": "2026-04-14",
        "summary": "This article by Stock Traders Daily provides a detailed analysis of Qiagen N.v. (QGEN), highlighting a near-term strong sentiment with a neutral mid and long-term outlook. It outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/target/stop loss zones, generated by AI models for different risk profiles. The analysis also includes multi-timeframe signal data for support and resistance levels.",
        "sentiment_score": 0.339133,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Is sample-to-insight leadership strong enough to unlock new upside",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-is-sample-to-insight-leadership-strong/69144198",
        "date": "2026-04-14",
        "summary": "This report analyzes Qiagen N.V.'s business model, its relevance in the U.S. and English-speaking markets, and the risks involved for investors. Qiagen focuses on sample-to-insight solutions in molecular diagnostics and life sciences, generating recurring revenue from high-margin consumables like reagents and kits. The company's growth is fueled by global demand for molecular diagnostics, advancements in gene and cell therapy, and its strong competitive position in sample prep technologies, thou",
        "sentiment_score": 0.451927,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more now for U.S. investors?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-molecular-diagnostics-edge/69143141",
        "date": "2026-04-14",
        "summary": "The article discusses why Qiagen N.V.'s molecular diagnostics capabilities are increasingly relevant for U.S. investors, highlighting the company's \"sample-to-insight\" business model and its comprehensive portfolio of tools. It covers key products, industry drivers, competitive strengths, and analyst views, while also addressing potential risks such as supply chain vulnerabilities and regulatory hurdles. Qiagen's focus on precise genomic testing and personalized medicine positions it as a key pl",
        "sentiment_score": 0.501946,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Does its genomics leadership deliver the biotech stability U.S. investors seek?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-does-its-genomics-leadership-deliver-the/69132422",
        "date": "2026-04-12",
        "summary": "Qiagen N.V., a leader in molecular diagnostics and life sciences tools, offers U.S. investors exposure to the growing genomics market through its Nasdaq listing. The company's business model relies on recurring revenue from consumables for sample preparation and analysis, providing stability in the biotech sector. With strong positions in key markets like North America and a focus on precision medicine, Qiagen is considered a steady compounder by analysts despite potential risks like reimburseme",
        "sentiment_score": 0.474381,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Massachusetts Financial Services Co. MA Increases Stock Position in Qiagen N.V. $QGEN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-massachusetts-financial-services-co-ma-increases-stock-position-in-qiagen-nv-qgen-2026-04-11/",
        "date": "2026-04-11",
        "summary": "Massachusetts Financial Services Co. MA recently increased its stock holdings in Qiagen N.V. by 1.1% during the fourth quarter, bringing its total to over 24 million shares valued at approximately $1.09 billion. This comes as Qiagen reported better-than-expected Q4 earnings and revenue, while setting optimistic guidance for FY2026. Despite a \"Hold\" consensus rating and a $55.20 price target, the stock shows mixed momentum near $40.90, with high institutional ownership.",
        "sentiment_score": 0.24081,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "How Investors May Respond To Qiagen (QGEN) Upgrade After Reaffirmed 5% Outlook And New Product Plans",
        "url": "https://www.sahmcapital.com/news/content/how-investors-may-respond-to-qiagen-qgen-upgrade-after-reaffirmed-5-outlook-and-new-product-plans-2026-04-07",
        "date": "2026-04-09",
        "summary": "Deutsche Bank upgraded Qiagen (QGEN) after the company reaffirmed its 5% growth target and highlighted new sample-preparation product launches expected in the second half of 2026. This comes as Qiagen navigates a CEO transition, discontinues some platforms, and focuses on next-generation diagnostics tools. The article suggests that while the upgrade and growth outlook instill confidence, the key for investors remains the successful execution of new product launches and management of increasing c",
        "sentiment_score": 0.414003,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QGEN PE Ratio & Valuation, Is QGEN Overvalued",
        "url": "https://intellectia.ai/en/stock/QGEN/valuation",
        "date": "2026-04-09",
        "summary": "Qiagen NV (QGEN) is currently considered undervalued, with its forward PE ratio of 12.82 significantly lower than its five-year average of 21.34. The fair price for QGEN is estimated to be between $62.67 and $75.77, compared to its current price of $41.01, indicating it is undervalued by 34.56%. While its P/S ratio is above the industry average, its strong revenue growth might not sustain this premium.",
        "sentiment_score": 0.317385,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "BlackRock Discloses Double-Digit Stake in Qiagen",
        "url": "https://www.tipranks.com/news/company-announcements/blackrock-discloses-double-digit-stake-in-qiagen",
        "date": "2026-04-08",
        "summary": "BlackRock, Inc. has reported a significant stake in Qiagen (QGEN), holding a combined capital interest of 10.67% and voting rights of 11.81% through various affiliated entities. This disclosure, made via the Dutch financial regulator AFM, highlights substantial institutional confidence in the life sciences company. Qiagen, a Netherlands-based firm specializing in molecular diagnostics, has a current average analyst rating of \"Hold\" with a $45.00 price target.",
        "sentiment_score": 0.406284,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "BlackRock Raises Substantial Stake in Qiagen to Over 10%",
        "url": "https://www.tipranks.com/news/company-announcements/blackrock-raises-substantial-stake-in-qiagen-to-over-10",
        "date": "2026-04-08",
        "summary": "Asset manager BlackRock has significantly increased its stake in Qiagen, now holding 10.66% of its share capital and 11.83% of voting rights. This enlarged, mostly indirect stake positions BlackRock as a major institutional investor, potentially influencing Qiagen's governance and market perception. Qiagen is a Netherlands-based life sciences company specializing in molecular diagnostics and listed on multiple exchanges including the NYSE.",
        "sentiment_score": 0.174891,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-04-08:newsml_PexXzGyka:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-04-08",
        "summary": "QIAGEN N.V. has released a voting rights announcement received from the AFM (Netherlands Authority For the Financial Markets) on April 8, 2026. The notification details a transaction on April 2, 2026, where BlackRock, Inc. was obliged to notify changes in its holdings in QIAGEN N.V., covering both ordinary shares and contracts for difference, held through various BlackRock entities. The announcement includes a detailed breakdown of shares and voting rights, both real and potential, highlighting ",
        "sentiment_score": 0.003507,
        "sentiment_label": "Neutral",
        "relevance_score": 0.347974,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. (NYSE:QGEN) Given Average Rating of \"Hold\" by Brokerages",
        "url": "https://www.marketbeat.com/instant-alerts/qiagen-nv-nyseqgen-given-average-rating-of-hold-by-brokerages-2026-04-04/",
        "date": "2026-04-04",
        "summary": "Twelve brokerages have given Qiagen N.V. (NYSE:QGEN) an average \"Hold\" rating, with a mean 12-month price target of $55.20. The company recently beat earnings and revenue estimates for its last quarter, posting $0.62 EPS on $540.4 million in revenue, and has provided positive guidance for fiscal year 2026. Institutional investors hold approximately 70% of the stock.",
        "sentiment_score": 0.228384,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.953246,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (QGEN) upgraded to buy by Deutsche Bank after 30% decline",
        "url": "https://www.msn.com/en-us/money/savingandinvesting/qiagen-qgen-upgraded-to-buy-by-deutsche-bank-after-30-decline/ar-AA201X7G",
        "date": "2026-04-03",
        "summary": "Deutsche Bank has upgraded Qiagen (QGEN) stock from hold to buy following a significant 30% decline in its share price. The upgrade reflects an improved risk/reward profile for the diagnostic test maker. Analyst Mark Massaro noted that while growth concerns persist, the valuation has become more attractive.",
        "sentiment_score": 0.540061,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-04-02:newsml_PexMgJMna:0-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-04-03",
        "summary": "QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, as informed by the AFM on April 2, 2026. The notification details transactions and holdings by Bank of America Corporation, showing a total capital interest and voting rights of 3.01% in QIAGEN N.V. The reported transactions occurred on March 30, 2026, and include direct and indirect holdings through various entities.",
        "sentiment_score": 0.013885,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Bank of America Discloses 3.01% Voting Stake in Qiagen",
        "url": "https://www.tipranks.com/news/company-announcements/bank-of-america-discloses-3-01-voting-stake-in-qiagen",
        "date": "2026-04-02",
        "summary": "Bank of America Corporation and its affiliates have disclosed a 3.01% capital and voting interest in Qiagen, a Netherlands-based life sciences company. This stake comprises both actual shares and derivatives like swaps and call options, highlighting Bank of America's position as a significant institutional shareholder. The disclosure provides increased transparency regarding Qiagen's ownership structure and potential influences on its shareholder dynamics.",
        "sentiment_score": 0.340146,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QGEN Technical Analysis & Stock Price Forecast",
        "url": "https://intellectia.ai/en/stock/QGEN/technical",
        "date": "2026-04-02",
        "summary": "The article provides a technical analysis and stock price forecast for Qiagen NV (QGEN), indicating a \"Sell\" consensus based on various technical indicators as of April 6, 2026. Key metrics like MACD and moving averages suggest a bearish trend, with the stock trading below its 60-day and 200-day moving averages. Despite some neutral signals from RSI and Stochastic Oscillator, the overall recommendation points towards a sell.",
        "sentiment_score": -0.420075,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline",
        "url": "https://www.insidermonkey.com/blog/qiagen-qgen-upgraded-to-buy-by-deutsche-bank-after-30-decline-1730551/?amp=1",
        "date": "2026-04-02",
        "summary": "Deutsche Bank upgraded Qiagen N.V. (NYSE: QGEN) to Buy from Hold, maintaining a $54 price target, after the stock declined over 30% since late January. The firm notes that Qiagen’s 2026 outlook is back-end heavy, common for Diagnostics and Life Sciences companies, and is reasonably reflected in current consensus estimates. Despite macroeconomic challenges, Qiagen reiterated its 5% full-year growth estimate, anticipating improved growth in the second half due to new sample-preparation product int",
        "sentiment_score": 0.327797,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline",
        "url": "https://finance.yahoo.com/sectors/healthcare/articles/qiagen-qgen-upgraded-buy-deutsche-183727878.html",
        "date": "2026-04-02",
        "summary": "Deutsche Bank has upgraded Qiagen (QGEN) to Buy from Hold, maintaining a $54 price target, after the stock declined over 30% since late January. The firm believes the decline has priced out any buyout premium and noted that Qiagen's 2026 outlook, like many in its sector, is back-end heavy. Qiagen reiterated its 5% full-year growth estimate, anticipating improved growth in the second half due to new product introductions.",
        "sentiment_score": 0.414678,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Oversold Opportunity in Molecular Diagnostics Leader for North American Investors",
        "url": "https://www.ad-hoc-news.de/news/ueberblick/qiagen-n-v-stock-oversold-opportunity-in-molecular-diagnostics-leader/69045464",
        "date": "2026-04-01",
        "summary": "Qiagen N.V. (NASDAQ:QGEN) shares are trading near 52-week lows, presenting a potential oversold opportunity for North American investors. Institutional investors like Allspring Global Investments have increased their stakes, and Deutsche Bank upgraded the stock to Buy, reflecting confidence in its molecular diagnostics leadership. The company's solid financial health, recurring revenue model, and strategic focus on genomics innovation position it for recovery and growth into 2026, despite broade",
        "sentiment_score": 0.490248,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-leader-in-molecular-diagnostics-faces-ceo-transition/69047905",
        "date": "2026-04-01",
        "summary": "Qiagen N.V. (ISIN: NL0012169213), a prominent molecular diagnostics leader, is undergoing a CEO transition while maintaining its 5% growth target for the year. North American investors are advised to monitor leadership changes, new product launches, and the company's strategic focus on innovation and sustainability. The company's resilience, diversified portfolio, and strong position in genomics tools make it an appealing option despite sector headwinds.",
        "sentiment_score": 0.2513,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Bruker appoints QIAGEN CEO Thierry Bernard to board of directors",
        "url": "https://www.investing.com/news/company-news/bruker-appoints-qiagen-ceo-thierry-bernard-to-board-of-directors-93CH-4592749",
        "date": "2026-04-01",
        "summary": "Bruker Corporation has appointed Thierry Bernard, the current CEO of QIAGEN N.V., to its board of directors, effective immediately. Bernard, who will step down from QIAGEN upon the appointment of his successor, brings extensive experience from his leadership roles at QIAGEN and bioMérieux SA. Frank Laukien, Bruker's CEO, stated that Bernard's expertise will aid the company's growth in life-science research, biopharma, and diagnostic solutions.",
        "sentiment_score": 0.008852,
        "sentiment_label": "Neutral",
        "relevance_score": 0.340765,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Oversold Opportunity in Sample-to-Insight Leader Amid Biotech Sector Shifts",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-oversold-opportunity-in-sample-to-insight-leader-amid/69042402",
        "date": "2026-04-01",
        "summary": "Qiagen N.V. shares are trading near 52-week lows, presenting a potentially oversold opportunity for North American investors interested in the molecular diagnostics and life sciences sector. The company, a leader in Sample-to-Insight solutions, has received analyst upgrades and seen increased institutional interest despite recent market pressure. Its strategic focus on high-growth areas like next-generation sequencing and precision medicine, coupled with its strong balance sheet, positions it fo",
        "sentiment_score": 0.332621,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/the-bull-case-for-qiagen-qgen-could-change-following-new-qua",
        "date": "2026-03-30",
        "summary": "Qiagen (QGEN) recently released new clinical and health economic data for its QuantiFERON-TB Gold Plus blood test, showing improved tuberculosis detection and reduced healthcare costs. This strengthens the investment case by enhancing the product's clinical and economic credibility. While this supports Qiagen's long-term potential, the company's immediate focus remains on factors like QIAstat-Dx uptake and macroeconomic pressures affecting margins.",
        "sentiment_score": 0.42288,
        "sentiment_label": "Bullish",
        "relevance_score": 0.969776,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/the-bull-case-for-qiagen-qgen-could-change-following-new-qua/amp",
        "date": "2026-03-30",
        "summary": "QIAGEN N.V. recently released new clinical and health economic data for its QuantiFERON-TB Gold Plus blood test, demonstrating improved tuberculosis detection and reduced lifetime healthcare costs compared to traditional methods. This evidence, supported by extensive studies, strengthens the test's role in preventive treatment and resource efficiency. The report suggests this expanded validation could impact Qiagen's investment narrative, particularly as the company pushes for increased adoption",
        "sentiment_score": 0.439717,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/qiagen-nv-hits-new-52-week-low-at-usd-3880-amid-declining-performance-3926234",
        "date": "2026-03-30",
        "summary": "QIAGEN NV has fallen to a new 52-week low of USD 38.80, marking a 15.36% decline over the past year. Despite strong debt servicing capabilities and record operating cash flow, the company's long-term growth prospects are limited, with operating profit growing at only 5.15% annually over the last five years. The stock's current valuation indicates a complex landscape for investors.",
        "sentiment_score": -0.649127,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection",
        "url": "https://www.sahmcapital.com/news/content/qiagen-qgen-valuation-check-as-new-quantiferon-tb-data-reinforces-leadership-in-tuberculosis-detection-2026-03-28",
        "date": "2026-03-29",
        "summary": "Qiagen (QGEN) is under renewed focus following new clinical and health economic data supporting its QuantiFERON-TB Gold Plus test for tuberculosis detection, alongside an upcoming global online event. Despite recent share price momentum fading, the company's valuation narrative suggests it is 29.6% undervalued, with a fair value of $55.46 against a current trading price of $39.07. This outlook is supported by expected revenue growth, improved margins, and the launch of new high-throughput automa",
        "sentiment_score": 0.337035,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-27:newsml_PexprN21a:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-27",
        "summary": "QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM (the Netherlands Authority For the Financial Markets). The notification details a transaction on March 23, 2026, where BlackRock, Inc. adjusted its holdings in Qiagen N.V. The distribution overview shows BlackRock's total capital interest at 10.44% and voting rights at 11.59%, held indirectly through various subsidiaries.",
        "sentiment_score": 0.015377,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}